ReP USP - Resultado da busca

Artigo de periodico
Acute inflammation Is a predisposing factor for weight gain and insulin resistance (2022)
Oliveira, Edson Mendes de ; Silva, Jacqueline Cavalcante ; Ascar, Thais P; Sandri, Silvana; Marchi, Alexandre Froes; Migliorini, Silene; Nakaya, Helder Takashi Imoto ; Fock, Ricardo Ambrósio ; Campa, Ana
Fonte: Pharmaceutics. Unidade: FCF
Assuntos: INFLAMAÇÃO, GANHO DE PESO, RESISTÊNCIA À INSULINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Edson Mendes de et al. Acute inflammation Is a predisposing factor for weight gain and insulin resistance. Pharmaceutics, v. 14, p. 1-13 art. 623, 2022Tradução . . Disponível em: https://doi.org/10.3390/pharmaceutics14030623. Acesso em: 09 nov. 2024.
APA
Oliveira, E. M. de, Silva, J. C., Ascar, T. P., Sandri, S., Marchi, A. F., Migliorini, S., et al. (2022). Acute inflammation Is a predisposing factor for weight gain and insulin resistance. Pharmaceutics, 14, 1-13 art. 623. doi:10.3390/pharmaceutics14030623
NLM
Oliveira EM de, Silva JC, Ascar TP, Sandri S, Marchi AF, Migliorini S, Nakaya HTI, Fock RA, Campa A. Acute inflammation Is a predisposing factor for weight gain and insulin resistance [Internet]. Pharmaceutics. 2022 ; 14 1-13 art. 623.[citado 2024 nov. 09 ] Available from: https://doi.org/10.3390/pharmaceutics14030623
Vancouver
Oliveira EM de, Silva JC, Ascar TP, Sandri S, Marchi AF, Migliorini S, Nakaya HTI, Fock RA, Campa A. Acute inflammation Is a predisposing factor for weight gain and insulin resistance [Internet]. Pharmaceutics. 2022 ; 14 1-13 art. 623.[citado 2024 nov. 09 ] Available from: https://doi.org/10.3390/pharmaceutics14030623
Artigo de periodico
Genetic variant ABCC1 rs45511401 is Associated with increased response to statins in patients with familial hypercholesterolemia (2022)
Hernandez, Carolina Dagli ; Borges, Jéssica Bassani ; Marçal, Elisangela da Silva Rodrigues; Freitas, Renata Caroline Costa de ; Mori, Augusto Akira ; Gonçalves, Rodrigo Marques; Faludi, André Arpad ; Oliveira, Victor Fernandes de ; Ferreira, Glaucio Monteiro ; Bastos, Gisele Medeiros ; Zhou, Yitian ; Lauschke, Volker Martin ; Cerda, Alvaro ; Hirata, Mario Hiroyuki ; Hirata, Rosario Dominguez Crespo
Fonte: Pharmaceutics. Unidade: FCF
Assuntos: HIPERCOLESTEROLEMIA, ESTATINAS, VARIAÇÃO GENÉTICA, FARMACOGENÉTICA, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HERNANDEZ, Carolina Dagli et al. Genetic variant ABCC1 rs45511401 is Associated with increased response to statins in patients with familial hypercholesterolemia. Pharmaceutics, v. 14, p. 1-20 art. 944, 2022Tradução . . Disponível em: https://doi.org/10.3390/pharmaceutics14050944. Acesso em: 09 nov. 2024.
APA
Hernandez, C. D., Borges, J. B., Marçal, E. da S. R., Freitas, R. C. C. de, Mori, A. A., Gonçalves, R. M., et al. (2022). Genetic variant ABCC1 rs45511401 is Associated with increased response to statins in patients with familial hypercholesterolemia. Pharmaceutics, 14, 1-20 art. 944. doi:10.3390/pharmaceutics14050944
NLM
Hernandez CD, Borges JB, Marçal E da SR, Freitas RCC de, Mori AA, Gonçalves RM, Faludi AA, Oliveira VF de, Ferreira GM, Bastos GM, Zhou Y, Lauschke VM, Cerda A, Hirata MH, Hirata RDC. Genetic variant ABCC1 rs45511401 is Associated with increased response to statins in patients with familial hypercholesterolemia [Internet]. Pharmaceutics. 2022 ; 14 1-20 art. 944.[citado 2024 nov. 09 ] Available from: https://doi.org/10.3390/pharmaceutics14050944
Vancouver
Hernandez CD, Borges JB, Marçal E da SR, Freitas RCC de, Mori AA, Gonçalves RM, Faludi AA, Oliveira VF de, Ferreira GM, Bastos GM, Zhou Y, Lauschke VM, Cerda A, Hirata MH, Hirata RDC. Genetic variant ABCC1 rs45511401 is Associated with increased response to statins in patients with familial hypercholesterolemia [Internet]. Pharmaceutics. 2022 ; 14 1-20 art. 944.[citado 2024 nov. 09 ] Available from: https://doi.org/10.3390/pharmaceutics14050944
Artigo de periodico
Polylactide nanocapsules attenuate adverse cardiac cellular effects of Lyso-7, a Pan-PPAR agonist/anti-inflammatory new thiazolidinedione (2021)
Garcia, Giani Martins; Roy, Jérôme; Pitta, Ivan R; Abdalla, Dulcinéia Saes Parra ; Guimarães, Andrea Grabe ; Mosqueira, Vanessa Carla Furtado ; Richard, Sylvain
Fonte: Pharmaceutics. Unidade: FCF
Assuntos: NANOPARTÍCULAS, ARTERIOSCLEROSE, SÍNDROME X METABÓLICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GARCIA, Giani Martins et al. Polylactide nanocapsules attenuate adverse cardiac cellular effects of Lyso-7, a Pan-PPAR agonist/anti-inflammatory new thiazolidinedione. Pharmaceutics, v. 13, p. 1-13 art. 1521, 2021Tradução . . Disponível em: https://doi.org/10.3390/pharmaceutics13091521. Acesso em: 09 nov. 2024.
APA
Garcia, G. M., Roy, J., Pitta, I. R., Abdalla, D. S. P., Guimarães, A. G., Mosqueira, V. C. F., & Richard, S. (2021). Polylactide nanocapsules attenuate adverse cardiac cellular effects of Lyso-7, a Pan-PPAR agonist/anti-inflammatory new thiazolidinedione. Pharmaceutics, 13, 1-13 art. 1521. doi:10.3390/pharmaceutics13091521
NLM
Garcia GM, Roy J, Pitta IR, Abdalla DSP, Guimarães AG, Mosqueira VCF, Richard S. Polylactide nanocapsules attenuate adverse cardiac cellular effects of Lyso-7, a Pan-PPAR agonist/anti-inflammatory new thiazolidinedione [Internet]. Pharmaceutics. 2021 ; 13 1-13 art. 1521.[citado 2024 nov. 09 ] Available from: https://doi.org/10.3390/pharmaceutics13091521
Vancouver
Garcia GM, Roy J, Pitta IR, Abdalla DSP, Guimarães AG, Mosqueira VCF, Richard S. Polylactide nanocapsules attenuate adverse cardiac cellular effects of Lyso-7, a Pan-PPAR agonist/anti-inflammatory new thiazolidinedione [Internet]. Pharmaceutics. 2021 ; 13 1-13 art. 1521.[citado 2024 nov. 09 ] Available from: https://doi.org/10.3390/pharmaceutics13091521
Artigo de periodico
Skin irritation Testing beyond tissue viability: fucoxanthin effects on inflammation, homeostasis, and metabolism (2020)
Tavares, Renata Spagolla Napoleão ; Maria-Engler, Silvya Stuchi ; Colepicolo, Pio ; Debonsi, Hosana Maria ; Schäfer-Korting, Monika ; Marx, Uwe; Gaspar, Lorena Rigo ; Zoschke, Christian
Fonte: Pharmaceutics. Unidades: FCF, IQ, FCFRP
Assuntos: ANTIOXIDANTES, METABOLISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TAVARES, Renata Spagolla Napoleão et al. Skin irritation Testing beyond tissue viability: fucoxanthin effects on inflammation, homeostasis, and metabolism. Pharmaceutics, v. 12, n. 2, p. 1-12 art. 136, 2020Tradução . . Disponível em: https://doi.org/10.3390/pharmaceutics12020136. Acesso em: 09 nov. 2024.
APA
Tavares, R. S. N., Maria-Engler, S. S., Colepicolo, P., Debonsi, H. M., Schäfer-Korting, M., Marx, U., et al. (2020). Skin irritation Testing beyond tissue viability: fucoxanthin effects on inflammation, homeostasis, and metabolism. Pharmaceutics, 12( 2), 1-12 art. 136. doi:10.3390/pharmaceutics12020136
NLM
Tavares RSN, Maria-Engler SS, Colepicolo P, Debonsi HM, Schäfer-Korting M, Marx U, Gaspar LR, Zoschke C. Skin irritation Testing beyond tissue viability: fucoxanthin effects on inflammation, homeostasis, and metabolism [Internet]. Pharmaceutics. 2020 ; 12( 2): 1-12 art. 136.[citado 2024 nov. 09 ] Available from: https://doi.org/10.3390/pharmaceutics12020136
Vancouver
Tavares RSN, Maria-Engler SS, Colepicolo P, Debonsi HM, Schäfer-Korting M, Marx U, Gaspar LR, Zoschke C. Skin irritation Testing beyond tissue viability: fucoxanthin effects on inflammation, homeostasis, and metabolism [Internet]. Pharmaceutics. 2020 ; 12( 2): 1-12 art. 136.[citado 2024 nov. 09 ] Available from: https://doi.org/10.3390/pharmaceutics12020136
Artigo de periodico
Use of nPSi-βCD composite microparticles for the controlled release of caffeic acid and pinocembrin, two main polyphenolic compounds found in a chilean propolis (2019)
Oyarzo, Dina Guzmán; Plaza, Tanya; Sánchez, Gonzalo Recio; Abdalla, Dulcinéia Saes Parra ; Salazar, Luis A; Montelongo, Jacobo Hernández
Fonte: Pharmaceutics. Unidade: FCF
Assuntos: PRÓPOLIS, POLIFENÓIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OYARZO, Dina Guzmán et al. Use of nPSi-βCD composite microparticles for the controlled release of caffeic acid and pinocembrin, two main polyphenolic compounds found in a chilean propolis. Pharmaceutics, v. 11, p. 1-17 art. 289, 2019Tradução . . Disponível em: https://doi.org/10.3390/pharmaceutics11060289. Acesso em: 09 nov. 2024.
APA
Oyarzo, D. G., Plaza, T., Sánchez, G. R., Abdalla, D. S. P., Salazar, L. A., & Montelongo, J. H. (2019). Use of nPSi-βCD composite microparticles for the controlled release of caffeic acid and pinocembrin, two main polyphenolic compounds found in a chilean propolis. Pharmaceutics, 11, 1-17 art. 289. doi:10.3390/pharmaceutics11060289
NLM
Oyarzo DG, Plaza T, Sánchez GR, Abdalla DSP, Salazar LA, Montelongo JH. Use of nPSi-βCD composite microparticles for the controlled release of caffeic acid and pinocembrin, two main polyphenolic compounds found in a chilean propolis [Internet]. Pharmaceutics. 2019 ; 11 1-17 art. 289.[citado 2024 nov. 09 ] Available from: https://doi.org/10.3390/pharmaceutics11060289
Vancouver
Oyarzo DG, Plaza T, Sánchez GR, Abdalla DSP, Salazar LA, Montelongo JH. Use of nPSi-βCD composite microparticles for the controlled release of caffeic acid and pinocembrin, two main polyphenolic compounds found in a chilean propolis [Internet]. Pharmaceutics. 2019 ; 11 1-17 art. 289.[citado 2024 nov. 09 ] Available from: https://doi.org/10.3390/pharmaceutics11060289

Unidades USP

ReP

Filtros

Autores

Autores USP

Assuntos

Agência de fomento

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos